Cohance Lifesciences Block Deal: Shares Worth ₹3,073 Crore Exchanged

On Thursday, September 18, Cohance Lifesciences shares saw a hit of over 5%, reaching a day low of ₹909.10 at 09:50 AM, after opening at ₹927.00 on BSE. The drop in Cohance Lifesciences shares came after the major block involving a trade of ~3.39 crore shares, equivalent to an 8.9% equity stake. The transaction was valued at ₹3,073 crore.

Block Deal Details

As per a news report by CNBC-TV18 earlier in the day, Jusmiral Holdings was expected to offload this 8.9% stake, or around 34.1 million shares, for approximately $350 million via block deals. Just a day prior, reports had indicated that Jusmiral Holdings planned to divest up to 5.1% of its holdings in the company.

The offer was pegged at ₹1,756 crore, with a floor price of ₹900 per share, representing a 6.9% discount to the stock’s previous closing price. A lock-in period of 210 days has reportedly been set for any further share sales by the seller.

IIFL Capital is acting as the book-running lead manager for the transaction, sources added.

As of the end of the June 2025 quarter, Jusmiral Holdings held a 33.34% stake in Cohance Lifesciences, according to exchange data.

Also Read: Waaree Energies To Offload 14.66% Stake Indosolar Through OFS

About Cohance Lifesciences

Cohance Lifesciences, formerly known as Suven Pharmaceuticals until its rebranding in May 2025, is a Hyderabad-based Contract Development and Manufacturing Organisation (CDMO). The company partners with global pharmaceutical, biotech, and specialty chemical firms, providing end-to-end solutions, from early-stage research and development to full-scale commercial manufacturing.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.